Structure via PubChem · Public domain (PubChem)
eplerenone
Sign in to saveEplerenone, sold under brand name Inspra among others, is an aldosterone antagonist used primarily in the treatment of heart failure with reduced ejection fraction (HFrEF), particularly following myocardial infarction. It may also be considered as an add-on therapy in resistant hypertension; however, the majority of evidence in this setting supports the use of spironolactone (another drug in a same class), with fewer studies directly evaluating eplerenone.
Key facts
- Drug.image
- Eplerenone.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 250
- Drug.tradename
- Inspra, others
- Drug.MedlinePlus
- a603004
- Drug.DailyMedID
- Eplerenone
- Drug.pregnancy_AU
- B3
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- C03
- Drug.ATC_suffix
- DA04
- Drug.legal_AU
- Schedule 4
- Drug.legal_US
- Rx-only
- Drug.bioavailability
- ~70%
- Drug.protein_bound
- ~50% (33–60%) (primarily to α1-acid glycoprotein)
- Drug.metabolism
- Liver (CYP3A4)
- Drug.metabolites
- , , , (All inactive)
- Drug.elimination_half life
- 4–6 hours
- Drug.excretion
- Urine (67%), feces (32%)
via Wikipedia infobox
Chemical data
- Formula
- C24H30O6
- Molecular weight
- 414.5 g/mol
- IUPAC name
- methyl (1R,2S,9R,10R,11S,14R,15S,17R)-2,15-dimethyl-5,5'-dioxospiro[18-oxapentacyclo[8.8.0.01,17.02,7.011,15]octadec-6-ene-14,2'-oxolane]-9-carboxylate
- SMILES
- C[C@]12CCC(=O)C=C1C[C@H]([C@@H]3[C@]24[C@H](O4)C[C@]5([C@H]3CC[C@@]56CCC(=O)O6)C)C(=O)OC
- InChIKey
- JUKPWJGBANNWMW-VWBFHTRKSA-N
- XLogP
- 1.4
- Polar surface area
- 82.2 Ų
- H-bond donors
- 0
- H-bond acceptors
- 6
- Formal charge
- 0
via PubChem
Research
2,033 papers- Eplerenone.Nature reviews. Drug discovery · 2003
- Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial.Journal of the American Society of Nephrology : JASN · 2022
- Comparative effectiveness and safety of eplerenone and spironolactone in patients with heart failure: a systematic review and meta-analysis.BMC cardiovascular disorders · 2024
- Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.The New England journal of medicine · 2003
- When to use spironolactone, eplerenone or finerenone in the spectrum of cardiorenal diseases.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024
via PubMed
Wikidata facts
- Mass
- 414.204239
Show 6 more facts
- chemical formula
- C₂₄H₃₀O₆
- isomeric SMILES
- C[C@]12CCC(=O)C=C1C[C@H]([C@@H]3[C@]24[C@H](O4)C[C@]5([C@H]3CC[C@@]56CCC(=O)O6)C)C(=O)OC
- canonical SMILES
- CC12CCC(=O)C=C1CC(C3C24C(O4)CC5(C3CCC56CCC(=O)O6)C)C(=O)OC
- NCI Thesaurus ID
- C47513
- defined daily dose
- 50
- Commons category
- Eplerenone
Sources (6)
via Wikidata · CC0
~6 min read
Article
11 sectionsContents
- Medical uses
- Heart failure
- Hypertension
- Central serous chorioretinopathy
- Adverse effects
- Interactions
- Pharmacology
- Society and culture
- Economics
- Brand names
- References
Eplerenone, sold under brand name Inspra among others, is an aldosterone antagonist used primarily in the treatment of heart failure with reduced ejection fraction (HFrEF), particularly following myocardial infarction. It may also be considered as an add-on therapy in resistant hypertension; however, the majority of evidence in this setting supports the use of spironolactone (another drug in a same class), with fewer studies directly evaluating eplerenone.
It is also a steroidal antimineralocorticoid of the spirolactone group and a selective aldosterone receptor antagonist (SARA).